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Summary We compared the antitumour effects of glycosylated LT (gLT), nonglycosylated LT and TNF
against a solid tumour in mice. We found that: (a) The systemic administration of gLT showed significant
antitumour activity. These effects were, however, quite small in nude mice. Nonglycosylated LT and TNF
attained the same degree of effectiveness as gLT, but at a 5-times higher dose. The serum half-life of gLT was
3-fold longer than that of nonglycosylated LT and 22-fold longer than that of TNF. (b) The effect of gLT was
significantly blocked by pretreatment with anti-asialo GM 1 antibody. Treatment with gLT produced a
significant reduction in numbers of tumour-regional mononuclear cells, which in turn, produced increases
intensive necrosis. (c) Mononuclear cells in the tumour tissues before gLT-injection were predominantly IL-2
receptor +/CD3 - cells and CD3 + cells. Pretreatment with the anti-asialo GM 1 antibody produced a drastic
reduction of IL-2 receptor +/CD3 - cells. These findings suggest that the efficient antitumour effect of gLT is
due to a longer serum half-life than that of nonglycosylated LT or TNF in vivo, and its function is largely
mediated by IL-2 receptor+/CD3 - cells.
Lymphotoxin (LT; TNF0) was first characterised as a
biological factor generated in response to T cell activation
that could mediate the cytolysis of tumour cells and other
targets (Ruddle & Wakoman, 1967; Granger & Kolb, 1968;
Dumonde et al., 1969; Rosenberg et al., 1973; Evans &
Heinbaugh, 1981). Later, human LT was purified and
sequenced, and it was found to be about 30% homologous to
tumour necrosis factor (TNF; TNFa) in its amino acid
sequence (Aggarwal et al., 1984, 1985a; Pennica et al., 1984;
Nedwin et al., 1985). Furthermore, both LT and TNF were
found to be linked to the human major histocompatibility
complex (MHC) (Spies et al., 1986), to share mainly a com-
mon cell-surface receptor (Aggarwal et al., 1985b; Patton et
al., 1986), and to have similar biological activities (Gray et
al., 1984). However, LT and TNF differ in some aspects, e.g.,
in their affinity to TNF receptors, in their adhesive properties
related to neutrophils and hematopoietic cells, in their ex-
pression of MHC class I antigen, and so on (Locksley et al.,
1987; Pober et al., 1987; Broudy et al., 1987; Andrews et al.,
1990; Murphy et al., 1988; Oster et al., 1987; Cuturi et al.,
1987; Beran et al., 1987). It has also been reported that
purified recombinant human TNF shows efficacy against
tumours in vivo (Sohmura et al., 1986; Palladino, 1987;
Manda et al., 1987; Asher et al., 1987; Watanabe et al., 1988;
Inagawa et al., 1988). However, there are few published data
for in vivo studies of glycosylated human LT(gLT), (Khan et
al., 1982; Papermaster et al., 1980; Ransom et al., 1982),
because the production of recombinant LT with sugar
moieties was not achieved until quite recently. Human lym-
photoxin genomic DNA has recently been cloned, and an
efficient system for producing human gLT in Chinese hamster
ovary cells has now been established in our laboratory
(Nakagawa et al., 1991). We have previously reported that
gLT, unexpectedly, had weak cytotoxicity against tumour
cells in vitro, but that it had a significant effect in vivo on
solid tumours and metastases (Mikami et al., 1989;
Funahashi et al., 1991). Combination therapy with human
interferon can induce greater synergistic efficacy than com-
binations of TNF and interferon (Kawatsu et al., 1990a).
Our results suggest that host immunity is important for
expressing the function of gLT. However, the detailed func-
tion of gLT has not been adequately explained. In this study,
we demonstrated the effectiveness of human gLT against a
solid tumour in mice, compared the results with those for
nonglycosylated LT and TNF, and attempted to analyse
tumour-regional mononuclear cells involved in its action.
Materials and methods
Mice
Female BALB/c and BALB/c nu/nu (-) mice, aged 6 weeks,
were obtained from Japan SLC Inc. (Hamamatsu, Japan).
They were fed a sterilised pellet diet and water ad libitum
under pathogen-free conditions.
Tumour
A Meth A fibrosarcoma was kindly provided by the Faculty
of Pharmaceutical Sciences, Teikyo University; it was main-
tained in ascites form in syngeneic BALB/c mice by weekly
intraperitoneal (i.p.) passage.
LTand TNF
Recombinant human gLT, produced by Chinese hamster
ovary cells through the expression of human LT genomic
DNA, was purified and characterised as described previously
(Nakagawa et al., 1991). Purified LT, consisting mostly of
171 amino acid residues (full length), was composed of three
species with molecular masses of 25, 23 (major) and 21 kDa
(very minor) as judged by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE). Amino acid
and sugar components of these gLT species were analysed,
and it was found that (1) 25kDa LT has Leu-Pro-Gly-Val-
Gly at N-terminus, carries both N-type sugar moieties
(molecular ratio; Man: Fuc: Gal:GlucNAc: NANAc = 3:
1.2:2.4: 4.0:1.3) and mucin-type sugar moieties (molecular
ratio; GalNAc:Gal:NANAc = 1: 1.06:1.14, and without
Man), (2) 23kDa carries N-type sugar moieties alone and
comprises 80% of the preparation, and (3) 21 kDaLT is the
same as the 23kDa species except that it lacks 15 amino acid
residues at the N-terminus, starts with Gln-His-Pro-Lys-Met
sequence. The specific activity of the purified gLT prepara-
tion was over 2 x IO'LMUmg-1 of protein in terms of
cytotoxicity to L-M cells in vitro. (The concentration of gLT
giving an ED50 in L-M cells after culture was defined as
1 LMUml-'.) The gLT preparation used in this study con-
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tained endotoxin at a concentration of less than 0.5 ngmg-'
of protein.
Nonglycosylated recombinant human LT, produced by
Escherichia coli through the expression ofhuman cDNA, was
purified by ion-exchange column chromatography to give a
single band on SDS-PAGE. Recombinant human TNF was
produced in the same manner. Purified TNF, having Met-
Ser-Ser-Ser at the N-terminus, consisted of 156 amino acid
residues (full length) and was 18kDa on SDS-PAGE. The
specific activities of nonglycosylated LT and TNF were over
2 x 106 LMUmg-' of protein. (The activity (LMUml-') was
calculated as the ratio of the highest dilution of nong-
lycosylated LT and TNF giving an ED,o in L-M cells to an
gLT standard.) The preparations of nonglycosylated LT and
TNF contained endotoxin at concentrations of less than
10 ngmg-' of protein. All preparations were diluted with
saline were buffered with 10mM phosphate-buffered saline
(pH7.2) and stored at -80°C. They were diluted with saline
just before use, and injected into mice at Smlkg-'.
Preparation ofserum
Blood samples were collected from the abdominal vein of
Meth A tumour-bearing mice 2 min to 3h after i.v. injection
of g-LT, nonglycosylated LT and TNF. The blood were
centrifuged at 3,000 rpm for 15 min at 4°C. The serum from
each sample was stored at - 80°C until use.
Assayfor LTactivity in serum
The biological activity of LTs and TNF in serum was deter-
mined by the original method of Ruff and Gifford (1981)
with slight modifications. Briefly, L929 cells were seeded at a
density of 3 x 104 cells in 96-well plastic tissue culture plates
(25860, Corning Glass Works, USA) in 0.2 ml of MEM
medium contained 5% foetal calf serum. After 20h of
incubation at 37°C in a humidified CO2 incubator, two-fold
serial dilutions of the samples with actinomycin D
(0.002mgml-', Calbiochem) were prepared in separate 96-
well plates. Then 0.2 ml of each dilution was transferred into
the corresponding well aspirated just before the transfer. The
plates were incubated for 20h at 37°C in a humidified 5%
CO2 atmosphere. The remaining viable cells were fixed with
glutaraldehyde and stained with 0.05% crystal violet. The
dye was extracted with 0.2 ml of a 0.5% sodium sulfate
solution and the absorbance at 590 nm was measured
photometrically in a Titertec Multiskan (Flow Lab.). The
highest dilution producing 50% cell lysis was taken as the
end point of LT activity. LT activity (LMUml-') was cal-
culated as the ratio of the end point of each sample to an
gLT standard.
Monoclonal antibodies (mAb)
For in vitro experiments, hamster anti-x P TcR and anti-'y 6
TcR mAb, and rat anti- Thyl.2, anti-CD4 (L3T4), and anti-
CD8 (Lyt2.2) mAb were purchased from PharMigen (San
Diego, CA) and Becton Dickinson & Co. (Mountain View,
CA), respectively. For in vivo tests, rabbit anti-asialo GM1
mAb and rat anti-CD4 (L3T4) mAb were purchased from
Wako Pure Chemical Industries Ltd. (Osaka, Japan). Rat
anti-CD8 mAb (Lyt2.2) was obtained from Cedarlane
Laboratories Ltd. (Ontario, Canada).
Evaluation ofanti-tumour activity
The largest and smallest diameters of solid tumours were
measured with vernier calipers. The estimated tumour weight
and the rate of inhibition of tumour growth were determined
by the following formulae: estimated tumour weight
(mg) = [longer ( (mm)] x [shorter .p (mm)]2 x 1/2, inhibition
rate = (1- W treated /W control) x 100, where W treated
and W control indicate the tumour weights of treated and
control mice, respectively. The statistical significance of
differences between values was analysed by Student's t-
test.
Mononuclear cellpreparationfrom tumour tissue
The treated tumour-bearing mice were killed 2h after the
gLT-injection. Untreated control mice were used in parallel.
Tumour mononuclear cells were prepared as described by
Abo (1991). Briefly, to obtain mononuclear cells, the tumours
were cut into small pieces with scissors, pressed through
100-gauge stainless steel mesh, and supended in RPMI 1640
medium. After being washed once with the medium, the cell
pellet was resuspended in 20 ml of the medium, and
mononuclear cells were isolated by Ficoll-Isopaque density
gradient centrifugation (1.090). In the mononuclear cell
preparation method applied here, the proportion of con-
taminated phagocytes was negligible (<4%). Numbers of
mononuclear cells were counted under a microscope, employ-
ing Turk's solution.
-& 3000-
E
2000 -
0
E
1000
0
7 14 21 7 14 21 7 14 21 7 14 21
Days after inoculation
Figure 1 Comparison of antitumour action of glycosylated LT(gLT), nonglycosylated LT and TNF. Meth A sarcoma (3 x 105 cells) was inoculated i.d. into BALB/c mice. gLT a, nonglycosylated LT b, TNF c, (4.1 x 104: *; 8.2 x 104: A; 1.6 x 105: U
LMUkg-') and saline (0) were injected i.v. six times, once every other day, beginning 1 week after the inoculation. BALB/c
nu/nu(-) mice d, also received gLT and saline in the same manner. Tumour weights represent the mean for five mice; bars indicate
SD Significant differences (*P<0.05) between control and treated groups were analysed by Student's t-test.MONONUCLEAR CELLS INVOLVED WITH GLYCOSYLATED gLT 449
Assayforpermeability
Mice with the Meth A tumour were injected i.v. with 0.2 ml
of Evans' blue solution (10 mgml-' in saline) with or without
gLT. Their solid tumours, which were removed 5 min after
the injection, were dissolved with lNKOH (1 ml/solid
tumour), extracted with 0.6NH2PO4/acetone (9 ml/solid
tumour), and measured photometrically at 620 nm.
Histology
For immunocytochemical examinations, tumour tissues were
fixed in periodate-lysine-paraformaldehyde (PLP) solution
and embedded in OCT compound (Lab-Tek Products, Miles
Laboratories Inc., Naperville. IL). Frozen sections were cut
and incubated with the above-mentioned mAb, i.e., anti- 1B
TcR, anti-? 6 TcR, anti-Thyl.2, anti-CD4, anti-CD8 and
anti-asialo GM1 mAb. After being washed in PBS, the sec-
tions were stained by the streptoavidin-biotin-complex-
peroxidase method and reacted with 3.3'-diaminobenzidine.
The tumour tissues were also fixed in 10% formaldehyde
solution, mounted with paraffin, cut into 3-jam sections,
stained with H-E solution, and then observed by light mic-
roscopy.
Immunofluorescence tests
The phenotype of murine mononuclear cells were analysed
by immunofluorescence tests using mAb. The surface
phenotypes of cells were identified by using mAb in conjunc-
tion with a two-colour immunofluorescence test (Abo et al.,
1991). The mAb used here included FITC-conjugated anti-
IL-2 receptor (kindly provided by Dr M. Miyasaka of Tokyo
Metrop. Inst., Japan), anti-CD4 (L3T4) and biotin-
conjugated anti-CD3 mAb (145-2C11; kindly provided by Dr
T. Nishimura), and CD8(Lyt2.2) mAb. A biotin-conjugated
reagent was developed with PE-conjugated avidin. The
fluorescence-positive cells were analysed with a FACScan
(Becton Dickinson & Co.).
Results
Comparison ofanti-tumour effects and serum half-life ofgLT,
nonglycosylated LTand TNF
To investigate the difference between gLT conjugated with
sugar moieties, nonglycosylated LT and TNF, we tested
antitumour effects under a regimen of i.v. treatment, beginn-
ing when the solid tumours had attained a diameter of
5-8 mm. Both gLT and nonglycosylated LT were
administered six times, once every other day. The maximal
dose of LT (1.6 x I05 LMU/mouse) used was equivalent to
one-fourth of the maximal tolerated dose obtained by i.v.
administration in mice. The time course of the tumour weight
is shown in Figure 1. A dose-dependent growth-inhibitory
effect of gLT was obtained in BALB/c (syngeneic) mice, and
a significant effect at maximal dose achieved almost 70%
(Figure 2). The dose response curve of TNF was parallel to
that of gLT, but nonglycosylated LT was not. However, both
nonglycosylated LT and TNF attained the same effectiveness
(ED50) at a dose and it was 5-times higher than that of
gLT.
gLT, nonglycosylated LT and TNF were injected i.v.
(bolus) into mice bearing Meth A sarcoma, and the decay in
their serum biological activity was examined. As shown in
Figure 3, their factors decayed nearly monophasically in
serum. The mean half-life of gLT was 1.7h, 3-fold longer
than that of nonglycosylated LT and 22-fold longer than that
of TNF; the area under the curve (AUC) of gLT was
1,763 LMUhml-', 3.5-fold greater than that of nong-
lycosylated LT and 136-fold greater than that of TNF.
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Figure 2 Dose-response inhibitory effects of gLT, nong-
lycosylated LT and TNF on growth of Meth A sarcoma. Meth A
sarcoma (3 x 105 cells) was inoculated i.d. into BALB/c mice.
gLT (0), nonglycosylated LT (A), TNF (A) and saline (control)
were injected i.v. at the indicated doses six times, once every
other day, beginning week after the inoculation. The rate of
inhibition of tumour growth was determined by the following
formula: inhibition rate = (1 - W treated / W control) x 100,
where W indicates the mean tumour weight of five mice.
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Figure 3 Comparison of serum concentrations of gLT, nong-
lycosylated LT and TNF in tumour-bearing mice. Meth A sar-
coma (3 x 105 cells) was inoculated i.d. into BALB/c mice. gLT
(0), nonglycosylated LT (A) and TNF (0) (0.83 x 105 LMU
kg-') were injected i.v. 7 days after the inoculation. Each point is
the average serum concentration in 3 mice when measured from 2
min to 3h after bolus injection. The best fit lines for the serum
decay curves were determined by a simplex curve-fitting
algorithm of APAS (Automated Pharmacokinetic Analysis
System) and the half-lives and AUC were calculated.
Effect ofhost immunity on antitumour action ofgLT
No direct cytotoxic activity of gLT was observed in vitro
(data not shown) and the in vivo effect was quite small in
BALB/c nu/nu(-)(nude) mice. Therefore, the effect of anti-
lymphocyte mAb on the antitumour action of gLT was
examined (Figure 4 and Table I). These mAb, which were
injected i.v., beginning 2 days before tumour inoculation,
clearly inhibited the antitumour effect of gLT. The inhibitory
effect of anti-asialo GM1 mAb was significant, while those of
the anti-CD4 and anti-CD8 mAb were partial. Although all
mAb did not have significant effects, treatments with mAb
tended not only to block the antitumour function of gLT,
but also to block that in the control group without gLT-
treatment at high doses.
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The time course of the number of mononuclear cells was
examined to determine whether the tumour-regional
mononuclear cells were affected by gLT. The numbers of
mononuclear cells did not change until 2h after the injection;
4h later, the number of these cells was significantly reduced,
to one-eighth of that noted before gLT-injection (Figure 5).
We also examined changes in the permeability of the tumour
vessels. Evans' blue solution was administered i.v. after gLT-
injection. Local permeability increased by almost 120% 1 h
after the administration of gLT. However, the permeability
rapidly lessened at 2h, followed by gradual reduction to
50%-60%, which continued until 6h. Thus, gLT-treatment
induced a biphasic reaction in the local vessels in the tumour.
Histological focal extravasation of mononuclear cells in the
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Figure 4 Effects of anti-asialo GMI, anti-CD4, and anti-CD8
mAb on the antitumour action of gLT. Meth A sarcoma
(3 x 105cells) was inoculated i.d. into BALB/c mice. gLT
(1.6 x 105LMUkg-1) was injected i.v. six times, once every other
day, beginning I week after the inoculation. Antibodies (anti-
asialo GM1I mAb a, anti-CD4 mAb b, and anti-CD8 mAb c;
I mg/mouse) were injected intravenously six times, once every
other day, beginning 2 days before the inoculation of Meth A
sarcoma. (0) saline; (A\) gLT; (O) mAb; (M) gLT + mAb.
Each tumour weight represents the average of four to five mice;
bars indicate standard deviations. Significant differences
(*P<0.05) between control and treated groups were analysed by
Student's t-test.
peripheral area was observed 2h after gLT-injection; after
this time, these cells almost disappeared, and intensive nec-
rosis was induced at 24h (Figure 6).
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Figure 5 Effects of gLT on the number of mononuclear cells in
tumour tissues and on the permeability of tumour vessels. (a)
Meth A sarcoma (3 x I05cells) was inoculated i.d. into BALB/c
mice (4 or 8 mice/group). Seven days later, these mice were
injected i.v. with 1.6 x I0 LMUkg-' ofgLT. The tumour tissues
were removed 0 to 6h after the gLT-injection, the mononuclear
cells were isolated by Ficoll-Isopaque from tumour tissues,
pooled, and counted under a microscope, using Turk's solution.
Each mononuclear cell value (0) represented the average ± SD
ofduplicate or triplicate results. (b) Mice were injected with gLT
or saline in the same manner. Evans' blue solution (0.2 ml) was
injected i.v. at the indicated times (0 to 6h). Five minutes later,
the tumours were removed, minced, homogenised, extracted with
1 NKOH, and measured photometrically at 620 nm. The %OD
(0) was calculated as follows: OD value for each gLT injection/
mean OD value for saline injection x 100. Closed circles and bars
show the mean %OD ± SD respectively, of five mice. Significant differences (*P<0.05) between 0 time and other times were
analysed by Student's t-test.
Table I Effects of host immunity on antitumour action of gLT
Tumour weight on day 21 Inhibition rate Treatment (mg) (%)
Saline 3110 1110 0 gLT 940 678* * 70 gLT + anti-asialo GM1 mAb (1 mg/mouse) 2337 85 | 25 Anti-asialo GM1 mAb (1 mg/mouse) 3260 1022 -5 Anti-asialo GMI mAb (3 mg/mouse) 3836 760 -24 gLT + anti-CD4 mAb (1 mg/mouse) 1423 ± 523* 55 Anti-CD4 mAb (I mg/mouse) 3261 ± 126 -5 Anti-CD4 mAb (3 mg/mouse) 3577 356 -15 gLT + anti-CD8 mAb (1 mg/mouse) 1588 ± 528* 50 Anti-CD8 mAb (1 mg/mouse) 2775 312 11 Anti-CD8 mAb (3 mg/mouse) 4641 ± 337 - 50
Meth A sarcoma (3 x 105cells) was inoculated i.d. into BALB/c mice. gLT (1.6 x 105 LMU kg-') was injected i.v. six times, once every other day, beginning I week after inoculation. Anti-asialo GM1 mAb, anti-CD4 mAb and anti-CD8 mAb were injected intravenously at the indicated dose (1-3 mg/mouse) six times, once every other day, beginning 2 days before the inoculation of Meth A sarcoma. Each tumour weight value represents the average of four to five mice; bars indicate standard deviations. Significant differences (*P <0.05) between control and treated groups were analysed by Student's t-test.MONONUCLEAR CELLS INVOLVED WITH GLYCOSYLATED gLT 451
Figure 6 Histology of tumour tissue of mice treated with gLT. Meth A sarcoma (3 x 1O0 cells) was inoculated i.d. into BALB/c
mice. Seven days later, these mice were injected i.v. with 1.6 x 105 LMUkg- of gLT. The tumour tissues were removed 0 a, 2 b, 6
c, 24 d,h after gLT-injection. a: focal extravasation of mononuclear cells in the peripheral area; b: necrotic area; (hematoxylin-eosin staining x 165).
Analysis oftumor-regional mononuclear cells before
gLT-injection
In the short-term experiment described above, no increase of
tumour-regional mononuclear cells was observed. Therefore,
we carried out immuno-cytochemical staining with mAb to
confirm whether mononuclear cells involved with the gLT
function were actually present in tumour tissues before gLT-
injection. As shown in Figure 7, various populations of
mononuclear cells, i.e., a ,B-T cell receptor (TcR)+, y 6
-TcR+, Thy-1.2+, CD4+, CD8+, and asialo GMI+
cells, were shown in these tissues. We also carried out a
two-colour immunofluorescence test, using FITC-conjugated
anti-IL-2 receptor P and PE-conjugated anti-CD3 mAb, to
compare IL-2 receptor and CD3 antigen expression patterns
in the mononuclear cells. The mononuclear cells in BALB/c
mice were shown to predominantly consist of IL-2
receptor+/CD3- (35%) and CD3 + cells (31%) (upper
panel in Figure 8). Pretreatment with the anti-asialo GMI
mAb produced to a significant reduction in IL-2 receptor+/
CD3- cells, one-seventh of that in non-treated mice; how-
ever, this pretreatment did not produce a reduction in the
CD3+ population. Next, a two-colour immunofluorescence
test, using anti-CD4 and anti-CD8 mAb, was also performed
to determine the proportion of the subpopoulation of CD3 +
cells (lower panel in Figure 8). The proportion of CD4+ to
CD8+ cells was 3:1, and no effect of the anti-asialo GM1
mAb was observed in these subpopulations. The two-colour
immunofluorescence test was also performed in nude mice
(Table II). However, all populations of mononuclear cells in
these animals were low, being equivalent to one-third of
those in syngeneic mice. Thus, the mononuclear cells
involved with gLT function, i.e., IL-2 receptor+/CD3-,
CD4+ cells and CD8 + cells were found to be present in the
tumour tissues, and the proportions of these cells were are
quite low in immune-defective nude mice.
Discussion
In this study, we investigated the usefulness of human gLT
conjugated with sugar moieties against a solid tumour in
mice and we examined the population of mononunclear cells
involved with its action.
The growth-inhibitory activity of gLT against a syngeneic
tumour was greater than that of TNF, which conversely had
a stronger growth-inhibitory activity than that of gLT in
vitro (Funahashi et al., 1991). In vivo a 5-fold greater dose of
TNF than of gLT was required to produce equivalent
effectiveness (Figures 1 and 2). A similar phenomenon was
observed in combination with y-interferon, which showed no452 I. FUNAHASHI et al.
Figure 7 Immunocytochemical examination of mononuclear cells in tumour tissues. Meth A sarcoma (3 x 105 cells) was inoculated
i.d. into BALB/c mice. Seven days after the inoculation, mononuclear cells in tumour tissues were immunocytochemically stained
with the mAb, anti-a PTcR a, anti-y 6 TcR b, Thyl.2 c, anti-CD4 d, anti-CD8 e, and anti-asialo GMl f, (x 660).
significant indications of acting additively or synergistically
(Kawatsu et al., 1990a). However, gLT, which is about 30%
homologous to TNF in amino acid sequence, has no disulfide
bridges, and a different structure of the central part of the
molecule from TNF in addition to possessing sugar moieties.
Therefore, we prepared nonglycosylated LT to test the effects
of sugar moieties. Although the dose-response curve of non-
glycosylated LT was quite different from gLT or TNF, non-
glycosylated LT also required a five-fold greater dose than
gLT to obtain equivalent effectiveness. It has been shown
that LT and TNF share a common receptor and have almost
the same affinity for their cell-surface receptors on 3T3 LI
adipocytes and U-937 histocytic lymphoma cells (Aggarwal et
al., 1985b; Patton et al., 1986). However, it has also reported
that the affinity of non-glycosylated LT for TNF receptors
on human endothelial cells is markedly lower than that of
TNF, and that the LT competes for TNF receptors at almost
100-fold greater concentrations than TNF (Locksley et al.,
1987). We have also demonstrated that the half-life of gLT
depends upon the N-type sugar moieties, not upon mucin-
type sugar moieties (Kawatsu et al., 1990b). In the present
study we have shown that nonglycosylated LT has a 3-fold
shorter serum half-life than gLT whilst the half-life of TNF is
1/22 that of gLT (Figure 3). We are still uncertain as to
whether the affinity of glycosylated LT for TNF receptors on
human cells is different from nonglycosylated LT or TNF; we
do not know enough about the details of the differences from
the structure of N-type sugar moieties, e.g. differences
between bi- and tri-antennas, or effects of their sialic acids, to
be able to explain why gLT expresses more efficient thera-
peutic activity. However, these findings suggest that the
differences between gLT and nonglycosylated LT or TNF
may arise from the longer half-life of gLT in serum, and the
differences of half-life in serum may be due to the affinity for
TNF receptors on endothelial cells.
The antitumour mechanisms of LT and TNF in vivo are
still not clear, but it has been suggested that these include
direct cytotoxic effects against tumour cells as well as indirect
effects, including augmentation of the host-mediated immune
response and modulation of endothelial cell hemostatic pro-
perties at the tumour site (Old, 1985). Therefore, we
examined the population of mononuclear cells involved with
its action. The antitumour effect of gLT was significantly
blocked by anti-asialo GM1 mAb, and depletion of CD4+
and CD8 + cells induced a partial reduction in the
antitumour activity of gLT (Figure 4 and Table I). This
phenomenon has been observed to greater extent in a pul-
monary metastasis model (Funahashi et al., 1991). These
results suggest that gLT function involves the activation of
asialo GM1+ cells. Recent studies have demonstrated that
CD4+ cells not only have a helper function but also a killer
activity (Crossland et al., 1991; Nishimura et al., 1992).MONONUCLEAR CELLS INVOLVED WITH GLYCOSYLATED gLT 453
Anti-asialo GM1 Ab- treated
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Figure 8 Two-colour immunofluorescence test of mononuclear cells in tumour tissues of BALB/c mice. Meth A sarcoma
(3 x IO' cells) was inoculated i.d. into BALB/c mice (eight mice/group). Anti-asialo GM 1 mAb (1.5 mg/mouse) was injected i.v. five
times, once every other day, beginning 2 days before tumour-inoculation. A control group was injected with saline in the same
manner. Seven days after the inoculation, the mononuclear cells were isolated from the tumour tissues, pooled, and analysed by
immunofluorescence tests using the following mAb: FITC-conjugated anti-II-2 receptor P and PE-conjugated aliquots of anti-CD3
(upper panel), and FITC-conjugated anti-CD4 and PE-conjugated aliquots of anti-CD8 (lower panel).
Table II Two-colour immunofluorescence test ofmononuclear cells in tumour tissue of nude
mice
% Fluorescence-Positive MNC
Mouse IL-2R +/CD3 - CD3 + CD4 +/CD8 - CD4 -/CD8 +
BALB/c 37 5.0 33 6.2 31 ± 6.5 8 + 0.7
BALB/c nu/nu(-) 14 0.7* 12 9.9* 4± 0.0* 2± 0.0*
Meth A sarcoma (3 x 105 cells) was inoculated i.d. into both BALB/c mice and BALB/c
nu/nu(-) mice (eight mice/group). Seven days later, the mononuclear cells (MNC) were
isolated from tumour tissues, pooled, and then analysed by immunofluorscence tests, using
the following mAb: FITC-conjugated anti-IL-2 receptorp and PE-conjugated aliquots of
anti-CD3, and FITC-conjugated anti-CD4 and PE-conjugated aliquots of anti-CD8. Each
value for % fluorescence-positive cells represents the mean ± SD of duplicate or triplicate
determinations. Significant differences (*P <0.05) between BALB/c and BALB/c nu/nu(-)
mice were analysed by Student's t-test.
Treatment with anti-CD3 mAb plus IL-2 induces the
augmentation of CD4+ cells (Garbrecht et al., 1988; Londei
et al., 1988), and the generation of an optimal CD8+ cell-
cytotoxic response requires help from CD4+ cells (Kern,
1988). It is well known that NK cells interact with T cells
(CD3 + cells) through cytokines such as interferons and IL-2.
These findings suggest that CD4+ orCD8+ cells stimulated
by gLT may also enhance the action of asialo GM1 + cells.
Anti-asialo GM1 mAb produced a significant reduction in
tumour-regional IL-2 receptor+/CD3 - cells (Figures 7 and
8), indicating that a major population of IL-2 receptor+/
CD3 - mononuclear cells is shared by asialo GM1 + cells,
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thus there is the possibility of interaction between asialo
GM1+ cells and CD4+ or CD8+ cells in the tumour area.
We found that gLT produced reductions in tumour regional
mononuclear cells and changes in the permeability of tumour
vessels with a similar time course (Figures 5 and 6). The role
of this transient increase in permeability is still uncertain, but
the reduction in permeability may explain the action of gLT
in inducing tumour necrosis and tumour regression. The
reduction in permeability may have been due not only to the
direct effect of gLT, but also to the indirect effect of tumour-
regional mononuclear cells being stimulated by gLT. Since
(1) anti-asialo GM1 mAb abolished the function of gLT, (2)
smaller tumour regional necrosis and lower efficacy are seen
in nude mice stimulated by gLT, and (3) low proportion of
both tumour-regional IL-2 receptor+/CD3- cells and
CD3+ cells are observed in nude mice (Table II). In any
case it is obvious that, for effector cells to express their
antitumour effect, the presence of these cells in certain quan-
tities, in addition to their activation, is necessary. The
findings described above also suggest that a combination of
gLT and LAK-therapy may be more efficient against esta-
blished tumours than therapy with either agent alone.
In conclusion, we have shown that the efficient antitumour
effect of gLT with N-type sugar moities is due to a longer
serum half-life than that of nonglycosylated LT or TNF in
vivo, and its activity is largely dependent on the function of
IL-2 receptor+/CD3- cells.
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